Cargando…

ADAM10 and ADAM17: New Players in Trastuzumab Resistance

Detalles Bibliográficos
Autores principales:	Duffy, Michael J., Crown, John, Mullooly, Maeve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294375/ https://www.ncbi.nlm.nih.gov/pubmed/25460503

Ejemplares similares

ADAM10: a new player in breast cancer progression?
por: Mullooly, Maeve, et al.
Publicado: (2015)

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
por: Duffy, Michael J, et al.
Publicado: (2011)

ADAM10 and ADAM17—Novel Players in Retinoblastoma Carcinogenesis
por: Van Meenen, Dario, et al.
Publicado: (2022)

Role of ADAM10 and ADAM17 in Regulating CD137 Function
por: Seidel, Jana, et al.
Publicado: (2021)

Upregulation of APP, ADAM10 and ADAM17 in the Denervated Mouse Dentate Gyrus
por: Del Turco, Domenico, et al.
Publicado: (2014)

Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids
por: Matthews, Alexandra L., et al.
Publicado: (2017)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

Role of ADAM10 and ADAM17 in the Regulation of Keratinocyte Adhesion in Pemphigus Vulgaris
por: Kugelmann, Daniela, et al.
Publicado: (2022)

LRP1 shedding in human brain: roles of ADAM10 and ADAM17
por: Liu, Qiang, et al.
Publicado: (2009)

Influence of Anoctamin-4 and -9 on ADAM10 and ADAM17 Sheddase Function
por: Leitzke, Sinje, et al.
Publicado: (2022)

Adam
Publicado: (1880)

Assessment of ADAM17 and ADAM10 proteins with CXCL10 and thyroid autoimmunity in vitiligo pathogenesis
por: Kılıc, Sevilay, et al.
Publicado: (2022)

The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas
por: Oh, S.-T., et al.
Publicado: (2016)

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
por: Sahin, Umut, et al.
Publicado: (2004)

Differential Surface Expression of ADAM10 and ADAM17 on Human T Lymphocytes and Tumor Cells
por: Ebsen, Henriette, et al.
Publicado: (2013)

ADAM10 and ADAM17 as Biomarkers Linked to Inflammation, Metabolic Disorders and Colorectal Cancer
por: Sikora-Skrabaka, Magdalena, et al.
Publicado: (2022)

ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?
por: Maas, Sanne L., et al.
Publicado: (2023)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
por: Orme, Jacob J., et al.
Publicado: (2020)

Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
por: Siney, Elodie J., et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17
por: Alabi, Rolake O., et al.
Publicado: (2021)

ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non-redundantly to ADAM17
por: Zatovicova, Miriam, et al.
Publicado: (2022)

ADAM 17 endopeptidase
Publicado: (2009)

Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17
por: Riethmueller, Steffen, et al.
Publicado: (2016)

ADAM17: A Therapeutic Target for Patients with Emphysema?
por: Jundi, Bakr, et al.
Publicado: (2021)

Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP
por: Sammel, Martin, et al.
Publicado: (2019)

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2014)

The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17
por: Zheng, Yuanpeng, et al.
Publicado: (2020)

Renal ADAM10 and 17: Their Physiological and Medical Meanings
por: Kato, Takashi, et al.
Publicado: (2018)

ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis
por: Zbodakova, Olga, et al.
Publicado: (2021)

Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice
por: Prinzen, Claudia, et al.
Publicado: (2009)

Exploring the Potential Role of ADAM 17 and ADAM 22 in the Etiology of Autism Spectrum Disorders
por: Al-Mazidi, Sarah H., et al.
Publicado: (2023)

Differential expression and localization of ADAM10 and ADAM17 during rat spermatogenesis suggest a role in germ cell differentiation
por: Urriola-Muñoz, Paulina, et al.
Publicado: (2014)

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates
por: Yoneyama, Toshie, et al.
Publicado: (2017)

How membrane asymmetry regulates ADAM17 sheddase function
por: Sommer, Anselm, et al.
Publicado: (2016)

Dr. A. Wellington Adams
Publicado: (1881)

The collectrin‐like part of the SARS‐CoV‐1 and ‐2 receptor ACE2 is shed by the metalloproteinases ADAM10 and ADAM17
por: Niehues, Rabea Victoria, et al.
Publicado: (2022)

ADAM10 and ADAM17 promote SARS‐CoV‐2 cell entry and spike protein‐mediated lung cell fusion
por: Jocher, Georg, et al.
Publicado: (2022)

ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment
por: Théret, Nathalie, et al.
Publicado: (2021)

Epidermal ADAM17 is dispensable for Notch activation
por: Groot, Arjan J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4e96q383m7sudmpm3anoonk53s